| Drug Name |
Enoxaparin |
| Drug ID |
BADD_D02438 |
| Description |
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.[L31393] Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313] |
| Indications and Usage |
For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. |
| Marketing Status |
Not Available |
| ATC Code |
B01AB01; B01AB12; C05BA03; S01XA14 |
| DrugBank ID |
DB01225
|
| KEGG ID |
D07510
|
| MeSH ID |
D017984
|
| PubChem ID |
772
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| Synonyms |
Enoxaparin | Enoxaparine | PK-10,169 | PK 10,169 | PK10,169 | PK-10169 | PK 10169 | PK10169 | EMT-967 | EMT 967 | EMT967 | Lovenox | Clexane | EMT-966 | EMT 966 | EMT966 |
